Fig. 5From: Targeting macrophages in hematological malignancies: recent advances and future directionsCurrent and potential CD47/SIRPα-targeted bispecific antibodies (BsAbs) in hematological malignancies: hematological malignancies can be treated with BsAbs that bind “don’t eat me” signal molecules expressed by macrophages and markers specific to tumor cellsBack to article page